profit from every €100 of sales.
€0€100
Virbac SA
€354.50-0.84% today
+0.0% since Dec 23, 25
1-year low €302.001-year high €384.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €19.69 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Virbac SA sold, what it kept, and what it did with the cash.
Sales went from €1.22 billion in 2022 to €1.46 billion in 2025, with €151 million of profit last year.
SalesProfit
Virbac SA handed back 13% of the cash it generated last year.
€12M
Free cash flow 2025€97M
Bought back its own shares–
Paid as dividends€12M
Cash vs. debt€123M vs. €289M
Virbac SA vs. similar companies
Virbac SA grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Virbac SA | 19.7× · Fair price | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads Virbac SA's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,216 | 1,247 | 1,397 | 1,465 | |
| 790 | 810 | 938 | 975 | |
| 183 | 186 | 228 | 230 | |
| 229 | 231 | 276 | 287 | |
| 122 | 121 | 145 | 151 | |
| 14.42 | 14.38 | 17.34 | 18.00 | |
| 65.0% | 64.9% | 67.1% | 66.6% | |
| 15.1% | 14.9% | 16.3% | 15.7% | |
| 10.0% | 9.7% | 10.4% | 10.3% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,334 | 1,456 | 1,849 | 1,914 |
| Cash | 177 | 176 | 150 | 123 |
| Total debt | 90 | 120 | 307 | 289 |
| Total liabilities | 494 | 546 | 805 | 789 |
| 840 | 900 | 1,043 | 1,125 | |
| 8 | 8 | 8 | 8 | |
| 14.5% | 13.5% | 12.2% | 12.0% | |
| 14.5% | 13.5% | 13.9% | 13.4% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 99 | 119 | 204 | 199 | |
| 54 | 60 | 80 | 102 | |
| 45 | 59 | 124 | 97 | |
| Dividends paid | 11 | 11 | 11 | 12 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 19.7×
- –
- 2.57
- 2.6×
- 2.0×
- 30.7×
- 10.9×
- 3.3%
- 5.1%
- 0.4%
Profitability
- 66.6%
- 15.7%
- 10.3%
- –
- 12.0%
- 13.0%
- –
- –
- –
- –
Growth
- +6.4%
- +7.7%
- –
- –
- −0.3%
Financial health
- 0.6×
- 0.26
- –
- 25.6×
- 1.53
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 21%of 952
Top 32%of 884
Top 34%of 601
Bottom 35%of 886
Top 33%of 987
0.4%of the share price, paid each year
On $1,000 invested$4a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
8.1% of its profit
Room to growStretchedMore than it earns: 12.5%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
63Pass
Benjamin Graham
57No pass
Philip Fisher
61Pass
Peter Lynch
33No pass
Joel Greenblatt
39No pass
Charlie Munger
52No pass
Terry Smith
40No pass
Questions about Virbac SA
Is Virbac SA a good stock to buy?
A solid business at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Virbac SA AI analysis
What does Virbac SA do?
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. It is in Drug Manufacturers - General, based in Carros, France, with 6,442 employees.
Does Virbac SA pay a dividend?
Yes. At today's price the dividend is 0.4% a year, about 8% of its yearly profit. In 2025 it paid out €12.1 million in dividends.
Is Virbac SA stock halal?
Yes. Virbac SA passes our halal screen: its business is permitted and its debt is 10% of its market value, under the 30% limit. How we check
Who are Virbac SA's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Virbac SA's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.